Business
Mesoblast treatment gets US panel’s key tick of approval – Sydney Morning Herald
The drug that Mesoblast has been trialling on some COVID-19 patients has just got the nod from a US regulator panel for treating children with severe responses to bone marrow transplants.
Stem cell treatment producer Mesoblast has recorded a significant win after the US FDA’s Oncologic Drugs Advisory Committee voted in favour of its flagship product for treating children with severe responses to bone marrow transplants.
The planned meeting of the US regulator had sent Mesoblast shares on a rollercoaster this week. The multi-billion company’s share price dropped more than 30 per cent in a single session on Tuesday after briefing papers released ahead of the meeting revealed the w…
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
Noosa News24 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
Noosa News18 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Noosa News23 hours agoEric Bana Is Back in Murder-Mystery Mode (and in Scenic Surroundings) in the Trailer for New Netflix Series ‘Untamed’